-
Mashup Score: 5News Details - 11 month(s) ago
Novo Nordisk will stop the once-weekly injectable semaglutide kidney outcomes trial, FLOW, based on interim analysis Bagsværd, Denmark, 10 October 2023 – Novo Nordisk today an nounced the decision to stop the kidney outcomes trial FLOW (Effect of semaglutide versus placebo on the progression of renal impairment in people with type 2 diabetes and chronic kidney disease). The decision to stop the trial is based on a recommendation from the independent Data Monitoring Committee (DMC) concluding that the
Source: www.novonordisk.comCategories: General Medicine News, NephrologyTweet
-
Mashup Score: 22News Details - 1 year(s) ago
To see all the news please click on the button
Source: www.novonordisk.comCategories: Expert Picks, Latest HeadlinesTweet-
3500 patient Flow Trial of #Semaglutide in diabetics with kidney disease stopped early due to effectiveness of drug in preventing progression of kidney disease. #annusmirabilis continues https://t.co/CwGbgHka3q
-
-
Mashup Score: 0News Details - 1 year(s) ago
To see all the news please click on the button
Source: www.novonordisk.comCategories: Cardiologists, Latest HeadlinesTweet-
Unstoppable #GLP1RA semaglutide ‼️ #FLOW, the kidney outcomes trial of once-weekly injectable semaglutide, has stopped early for overwhelming efficacy based on interim analysis. More protection for our patients. https://t.co/qGtV75oaxZ https://t.co/d6mFOIwnwf
-
-
Mashup Score: 7News Details - 1 year(s) ago
To see all the news please click on the button
Source: www.novonordisk.comCategories: Cardiologists, Latest HeadlinesTweet-
RT @Nephro_Sparks: Wow! FLOW stopped early for efficacy! Another huge win for CKD https://t.co/4ZFPYqoRiR
-
-
Mashup Score: 4News Details - 1 year(s) ago
Novo Nordisk will stop the once-weekly injectable semaglutide kidney outcomes trial, FLOW, based on interim analysis Bagsværd, Denmark, 10 October 2023 – Novo Nordisk today announced the decision to stop the kidney outcomes trial FLOW (Effect of semaglutide versus placebo on the progression of renal impairment in people with type 2 diabetes and chronic kidney disease). The decision to stop the trial is based on a recommendation from the independent Data Monitoring Committee (DMC) concluding that the
Source: www.novonordisk.comCategories: Cardiologists, Latest HeadlinesTweet-
After CREDENCE, DAPA-CKD, & EMPA-KIDNEY, FLOW is 4th RCT in CKD to be stopped early. All 4 RCTs are event-driven; 3 were stopped at 50-60% accrual of planned events. How many of planned 854 events accrued in FLOW? Last time a HF RCT was stopped early? https://t.co/poTq0xN8Lb
-
Kidney outcomes trial of the GLP-1RA semaglutide 💉in patients w/ T2D + CKD (FLOW) stopped early for efficacy https://t.co/Cp9qSax66Y https://t.co/3LncTHJRI7
-
-
Mashup Score: 144News Details - 1 year(s) ago
Novo Nordisk will stop the once-weekly injectable semaglutide kidney outcomes trial, FLOW, based on interim analysis Bagsværd, Denmark, 10 October 2023 – Novo Nordisk today announced the decision to stop the kidney outcomes trial FLOW (Effect of semaglutide versus placebo on the progression of renal impairment in people with type 2 diabetes and chronic kidney disease). The decision to stop the trial is based on a recommendation from the independent Data Monitoring Committee (DMC) concluding that the
Source: www.novonordisk.comCategories: Cardiologists, Latest HeadlinesTweet-
2023, the year the #GLP1RA semaglutide can’t lose! #FLOW, the kidney outcomes trial of once-weekly injectable semaglutide, has stopped early for overwhelming efficacy based on interim analysis Massive news, results in Q1 2024 https://t.co/NIwf8km7Oy https://t.co/deCTcdbxpe
-
A remarkable transformation of care for people with diabetes and kidney disease in less than a decade. Before? Limited to only to RAS blockade. Now? Combination therapy with: - RASi - SGLT2i - GLP-1 RA - ns-MRA 4 pillars of care for diabetes & CKD https://t.co/zHoEs9vx4E https://t.co/kFkcHHcUoy
-
-
Mashup Score: 9News Details - 1 year(s) ago
To see all the news please click on the button
Source: www.novonordisk.comCategories: Cardiologists, Latest HeadlinesTweet-
SELECT trial: Among 17k w overweight/obesity (BMI >27) & CVD but w/o diabetes, semaglutide 2.4mg sc v placebo led to 20% reduction in MACE https://t.co/yiQRvpxv3W @novonordisk
-
-
Mashup Score: 125News Details - 1 year(s) ago
Bagsværd, Denmark, 8 August 2023 – Novo Nordisk today announced the headline results from the SELECT cardiovascular outcomes trial. The double-blinded trial compared subcutaneous once-weekly semaglutide 2.4 mg with placebo as an adjunct to standard of care for prevention of major adverse cardiovascular events (MACEs) over a period of up to five years. The trial enrolled 17,604 adults aged 45 years or older with overweight or obesity and established cardiovascular disease (CVD) with no prior history of
Source: www.novonordisk.comCategories: Expert Picks, Latest HeadlinesTweet-
Major Breaking News: A once weekly injection of of obesity drug #Semaglutide reduces the risk of major adverse cardiovascular events by 20% in adults who are overweight or obese in the SELECT trial https://t.co/s4c7W8B5Qn
-
HUGE result! SELECT RCT of semaglutide reduces composite of heart attack, stroke, & cardiovascular death in patients w/o diabetes but w/ history of CVD & overwt/obesity Need to see full report, but likely this will be std secondary prevention tx https://t.co/xQ8v4kMPQ8 https://t.co/aa5z3P0loR
-
the SELECT randomised trial of Ozempic/semaglutide v placebo reduced Heart attacks/strokes/CV death by 20% in non diabetic adults with higher BMI & established cardiovascular disease (CVD) we may be giving all overweight CAD patients GLP1s @PCCS_UK https://t.co/byfED5AC8W
-
-
Mashup Score: 4Changing Diabetes in Children - 3 year(s) ago
Our Changing Diabetes in Children programme (CDiC) is changing the future for children with type 1 diabetes in low and middle income countries.
Source: www.novonordisk.comCategories: Latest Headlines, PediatricsTweet-
#ISPAD is happy to have been part of the #ChangingDiabetesInChildren #Hackathon this past weekend, hacking #DigitalHealth innovations for #Type1Diabetes. More details to come and visit https://t.co/l1PypEW10Y to learn more! @NovoNordisk @Roche @HarvardChanSPH @mithackmed https://t.co/3vL5eeZCKf
-
-
Mashup Score: 0Changing Diabetes in Children - 3 year(s) ago
Our Changing Diabetes in Children programme (CDiC) is changing the future for children with type 1 diabetes in low and middle income countries.
Source: www.novonordisk.comCategories: Latest Headlines, PediatricsTweet-
#Type1Diabetes requires a high level of patient knowledge. Together with #ChangingDiabetesinChildren, we’ve developed patient education materials to support children and youth like Matthewos. The materials are available in 5 languages for download here: https://t.co/3he3TaefBp https://t.co/6s2q2J3xPG
-
also @nephroseeker suggests the story of GLP-1 in CKD (if Kim K and Oprah take it, why should we be left behind?!) The FLOW press release https://t.co/PKapA4aIAb leading to dialysis stocks tanking No results yet, but good story? #TopNephrology